Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck

NCT00185835 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Carcinoma, Squamous Cell

Interventions

DRUG: ZD-1839
DRUG: Cisplatin

Sponsor

Stanford University

Collaborators

[object Object]
[object Object]